Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to lymphokine – cytokine – or other secreted growth...
Reexamination Certificate
2007-03-08
2009-06-02
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to lymphokine, cytokine, or other secreted growth...
C514S011400
Reexamination Certificate
active
07541018
ABSTRACT:
In one embodiment, a method for treating a cancerous disease is provided which includes characterizing a disease by an overexpression of one or more somatostatin receptors, and exposing the one or more somatostatin receptors to a pharmaceutical composition comprising a somatostatin analogue which binds to the one or more somatostatin receptors. In one example, the somatostatin analogue may have the general formula:wherein Z is optionally present or absent and when present is selected from the group consisting of DOTA-based chelators, DTPA-based chelators, NOTA-based chelators, carbonyl compounds, hydrazino nicotinamide, N4-chelators, desferrioxamine, NXSY-chelators, tyrosine for halogenation, a fluorescent dye, and biotin; L is optionally present or absent and when present is a linker molecule; X1 is a symmetric or asymmetric diamino acid containing 3 or 4 consecutive carbon atoms; X2 is a positively charged natural or unnatural amino acid, an arginine mimic, citrulline, or a neutral amino acid; X3 is phenylalanine, Ala-[3-(2-thienyl)], α-naphthylalanine, or β-naphthylalanine; X4 is an aromatic amino acid; X5 is threonine or serine; and X6 is phenylalanine, Ala-[3-(2-thienyl)], α-naphthylalanine, or β-naphthylalanine.
REFERENCES:
patent: 4261885 (1981-04-01), Sakakibara et al.
patent: 6051206 (2000-04-01), Dean et al.
patent: 6180082 (2001-01-01), Woltering et al.
patent: 6930088 (2005-08-01), Hornik et al.
patent: 7192570 (2007-03-01), Maecke et al.
patent: 2004/0242842 (2004-12-01), Maecke et al.
patent: WO 03/014158 (2003-02-01), None
Hoyer, et al. “Classification and nomenclature of somatostatin receptors,” Trends in Pharmacological Sciences, Elsevier Trends Journal Cambridge, GB, vol. 16, No. 3, Mar. 1995, pp. 86-88, XP004207465.
International Search Report dated Nov. 29, 2002 for International Application No. PCT/EP/02/09004.
Reubi, et al. “A selective analog for the somatostatin SST1-receptor surtype expressed by human tumors,” European Journal of Pharmacology, Amsterdam, NL, Mar. 12, 1998, pp. 103-110, XP000876543.
Scicinski, et al. “The solid phase synthesis of a series of tri-substituted hydantoin ligands for the somatostatin SST5 receptor,” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 8, No. 24, Dec. 15, 1998, pp. 3609-3614, XP004150376.
Eisenwiener Klaus-Peter
Maecke Helmut Robert
Reubi Jean Claude
Rink Hans
Patterson & Sheridan L.L.P.
Russel Jeffrey E
University of Bern
LandOfFree
Treatment process using somatostatin analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment process using somatostatin analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment process using somatostatin analogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4145696